Licence to publish

We do not require authors to transfer copyright. Instead, authors are requested to sign and return a ‘licence to publish’ once an article has been accepted for publication (version of license will depend on open access option — see Author options post-acceptance below). Authors can select the most suitable form of open access.

Author options post-acceptance

Open Access – Green

Authors of review articles are encouraged to submit the author’s version of the accepted paper (the unedited manuscript) to their funding body’s archive for public release six months after publication. In addition, authors are encouraged to archive this version of the manuscript in their institution’s repositories and on their personal websites six months after publication.

Open Access – Gold

Authors of peer-reviewed articles can also opt to pay an article processing charge (in lieu of the standard publication charges) for their accepted articles to be open access online and freely accessible immediately upon publication. By paying this charge, authors are also permitted to post the final, published version of their article on a website, institutional repository or other free public server immediately on publication.

Open access articles can be published either under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International License, a Creative Commons Attribution-Noncommercial-Share Alike 4.0 International License, or a Creative Commons Attribution 4.0 International License at the free choice of the authors.

Pharmaceutical Journal Publications’ publishing policies ensure that authors can fully comply with the public access requirements of the major funding bodies worldwide ( However, it is the author’s responsibility to take the necessary actions to achieve compliance. This may include self-archiving or choosing open access publication under the appropriate licence type choice.


Last updated
The Pharmaceutical Journal, Licence to publish;Online:DOI:10.1211/PJ.2015.20200046

You may also be interested in